Editorials |
From Kings College London, Division of Asthma, Allergy, and Lung Biology, School of Medicine, London, UK.
Correspondence to Philip I Aaronson, Room 2:20, New Hunts House, Guys Hospital campus, Kings College London, London SE1 1UL, UK. E-mail philip.aaronson{at}kcl.ac.uk
See related article, pages 15281537
Key Words: TRP channels hypoxia-inducible factor HIF-1 chronic hypoxia pulmonary arteries pulmonary hypertension
| Introduction |
|---|
|
|
|---|
| Effects of Chronic Hypoxia on Pulmonary Arteries: A Role for TRPC Channels |
|---|
|
|
|---|
On a cellular level, CH causes PASMC membrane depolarization associated with a reduced expression and function of voltage-gated K+ channels.4,5 This has been proposed to contribute to PASMC proliferation by causing a rise in [K+]i and inhibiting apoptosis.6 A rise in the basal [Ca2+]i of PASMC has also been reported.7,8 This does not appear to be primarily caused by the opening of voltage-dependent (L-type) Ca2+ channels secondary to membrane depolarization, because nifedipine had little7 or no8 effect on [Ca2+]i in PASMCs from chronically hypoxic rats. Similarly, treatment with Ca2+ channel antagonists has more often than not failed to reverse SPH or prevent its development in humans and animals.911
Although depolarization might theoretically raise [Ca2+]i by promoting IP3-mediated release of Ca2+ from intracellular stores,12 it seems increasingly evident that it is an increased expression of channels incorporating TRPC1 and TRPC6 proteins which is largely responsible for raising PASMC [Ca2+]i during CH, and that this contributes to the pulmonary vascular remodelling and increased reactivity which ensue. A burgeoning literature has established that numerous TRP protein isoforms, mainly of the TRPC family, are expressed in vascular smooth muscle, and that they are involved in nonvoltage-gated Ca2+ channel influx stimulated by receptor activation, store depletion, and cell stretch.13 TRPC channels may be particularly important in small PA even in normoxia, as vasoconstrictor-induced contraction in these arteries appears to be more dependent on nonvoltage-gated Ca2+ influx pathways than on L-type Ca2+ channels, whereas systemic arteries of similar diameter demonstrate the opposite dependency.14 Expression of TRPC1 and TRPC6 has been consistently observed in PASMCs, with expression of TRPC3 and TRPC4 also variably detected.7,1518
There is extensive evidence that cell cycle progression is Ca2+-dependent, as are the activities of multiple transcription factors.19 Yuan and colleagues demonstrated that PASMC proliferation was abolished when Ca2+ influx and release from the sarcoplasmic reticulum were prevented. TRPC1 was shown to play a crucial role in supplying Ca2+ for the growth of these cells, because their proliferation was associated with its increased expression, as well as a rise in both store-operated Ca2+ entry (SOCE) and in basal [Ca2+]i. Moreover, knockdown of TRPC1 expression strongly suppressed PASMC proliferation and SOCE.15,17 Subsequently, Lin and coworkers7 described upregulation of both SOCE and OAG-stimulated (ie, receptor-activated) Ca2+ influx in PASMCs from chronically hypoxic rats. Experiments using La3+, which differentially blocked these two pathways, indicated that it was SOCE which was mainly responsible for the elevated [Ca2+]i and basal tone in PA from hypoxic animals. CH also strongly enhanced the mRNA/protein expression of TRPC1 and TRPC6 (but not TRPC3). siRNA knockdown of TRPC1 and TRPC6 selectively suppressed SOCE and OAG-induced Ca2+ influx, respectively. The reports indicate that TRPC1 upregulation probably contributes to the increased basal pulmonary tone and hyperplasia/hypertrophy of the pulmonary vasculature caused by CH, whereas a rise in TRPC6 expression could promote the greater responsiveness to vasoconstrictors which also occurs.
| HIF-1 and Pulmonary Hypertension |
|---|
|
|
|---|
, is regulated by cellular O2 levels, as is its binding to translational coactivators. Under normoxic conditions, HIF-1
is hydroxylated by specific enzymes in an O2-dependent manner on key proline and asparaginine residues, accelerating its degradation and also causing functional inhibition. However, as O2 levels fall, hydroxylation decreases and the concentration of functional HIF-1 dimer rises. This allows it to promote the transcription of genes for numerous proteins, including erythropoietin, VEGF, and multiple glycolytic enzymes, which are crucial for adaptation to hypoxia.20,21
A role for HIF-1 in mediating the pulmonary responses to CH was first demonstrated by Yu et al,22 who showed that the development of right ventricular hypertrophy, vascular remodelling, and SPH was delayed in Hif1a/+ compared with Hif1a+/+ mice. Similarly, PASMC hypertrophy, membrane depolarization, and K+ current attenuation elicited by CH were markedly reduced in the HIF-1
heterozygotes, compared with controls.23
The study by Wang et al1 now provides compelling evidence that the developing stories of HIF-1 and TRPC channels in the pulmonary vascular response to CH form part of the same narrative. The authors first confirm previous observations of elevated [Ca2+]i and SOCE in transiently-cultured PASMCs from rats made hypoxic for 21 days. They then show that in vivo chronic hypoxia in both rats and control mice results in an upregulation of the expression of protein and mRNA for TRPC1 and TRPC6, but not TRPC4. Crucially, they demonstrate that the increases in basal [Ca2+]i and TRPC1/6 expression are absent in HIF1a+/mice. Accordingly, overexpression of a constitutively active form of HIF-1a also increases the expression of TRPC1/6, but not TRPC4.
A key unresolved issue relates to the extent to which an increased expression of TRPC channels in pulmonary smooth muscle actually contributes to the overall sequence of events leading to secondary pulmonary hypertension. This question will only be answered when the in vivo effects of molecular or pharmacological ablation of TRPC1/6 signaling during CH are assessed. However, regardless of the centrality of this particular effect of HIF-1 to the pathogenesis of SPH, a clear implication of a series of studies from the Johns Hopkins group and its collaborators is that HIF-1 is probably responsible for multiple CH-induced alterations in the pulmonary vasculature, including the downregulation of K+ channels (Figure). Of particular importance in CH is the RhoA/Rho-kinase system, now increasingly seen as a central player in SPH.11 CH has been shown to upregulate the expression of Rho-kinase but not RhoA in PA.24 Although HIF-1 conversely downregulates Rho-kinase and increases RhoA expression, at least in fibroblasts,25 its possible role in controlling the expression of RhoA/Rho-kinase in the PA during CH remains unknown, and now becomes of great interest.
|
A variety of drugs are available which decrease the activity of HIF-1, although as yet no direct and specific inhibitors of HIF-1 have been described.21 Interest in the therapeutic targeting of HIF-1 is presently focused on suppressing its involvement in multiple cancers, however examination of the effects of pharmacological inhibitors of HIF-1 on the development of hypoxia-induced pulmonary hypertension in animal models would now also seem to be warranted.
| Acknowledgments |
|---|
This work was supported by the Wellcome Trust and the British Heart Foundation.
Disclosures
None.
| Footnotes |
|---|
| References |
|---|
|
|
|---|
. J Clin Invest. 1999; 103: 691696.[Medline]
[Order article via Infotrieve]
deficiency impairs pulmonary arterial myocyte electrophysiological responses to hypoxia. Am J Physiol Lung Cell Mol Physiol. 2001; 281: L202L208.Related Article:
This article has been cited by other articles:
![]() |
W. Wu, O. Platoshyn, A. L. Firth, and J. X.-J. Yuan Hypoxia divergently regulates production of reactive oxygen species in human pulmonary and coronary artery smooth muscle cells Am J Physiol Lung Cell Mol Physiol, October 1, 2007; 293(4): L952 - L959. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2006 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |